Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Biontech Se ADR (BNTX)

Biontech Se ADR (BNTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 34,864,128
  • Shares Outstanding, K 242,685
  • Annual Sales, $ 22,451 M
  • Annual Income, $ 12,177 M
  • 60-Month Beta 0.25
  • Price/Sales 1.84
  • Price/Cash Flow 2.82
  • Price/Book 1.87
Trade BNTX with:

Options Overview Details

View History
  • Implied Volatility 41.05% ( +0.58%)
  • Historical Volatility 44.36%
  • IV Percentile 1%
  • IV Rank 1.10%
  • IV High 93.44% on 03/08/22
  • IV Low 40.47% on 01/26/23
  • Put/Call Vol Ratio 3.60
  • Today's Volume 3,920
  • Volume Avg (30-Day) 2,936
  • Put/Call OI Ratio 1.12
  • Today's Open Interest 51,522
  • Open Int (30-Day) 72,385

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate 8.51
  • Number of Estimates 5
  • High Estimate 9.93
  • Low Estimate 7.03
  • Prior Year 13.93
  • Growth Rate Est. (year over year) -38.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
139.05 +3.32%
on 01/20/23
159.26 -9.80%
on 12/28/22
-16.20 (-10.13%)
since 12/27/22
3-Month
133.50 +7.61%
on 10/28/22
188.99 -23.98%
on 12/15/22
+8.08 (+5.96%)
since 10/27/22
52-Week
117.08 +22.70%
on 06/22/22
189.07 -24.02%
on 03/30/22
-10.88 (-7.04%)
since 01/27/22

Most Recent Stories

More News
Novavax (NVAX) COVID Jab Aids Growth, Overdependence a Challenge (revised)

Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.

PFE : 43.79 (-1.04%)
MRNA : 189.35 (-2.01%)
NVAX : 11.29 (+2.82%)
BNTX : 143.66 (+0.79%)
FDA Panel Endorses Simplification of COVID-19 Vaccine Strategy

An FDA advisory committee unanimously votes in favor of using the same COVID-19 vaccine strain composition for primary series and booster doses.

PFE : 43.79 (-1.04%)
MRNA : 189.35 (-2.01%)
NVAX : 11.29 (+2.82%)
BNTX : 143.66 (+0.79%)
Mergers and Acquisitions in 2023 Off To A Strong Start

Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road.

UNH : 486.05 (-1.31%)
LHCG : 156.74 (-0.72%)
AZN : 65.53 (-0.70%)
BNTX : 143.66 (+0.79%)
CVS : 87.78 (+0.14%)
SGFY : 28.42 (-0.66%)
MRNA : 189.35 (-2.01%)
GILD : 83.73 (+0.13%)
LPTX : 0.6407 (-4.33%)
SWAV : 187.83 (-3.50%)
NVCN : 27.75 (-0.36%)
SNY : 48.49 (-0.66%)
Can Pfizer (PFE) Beat Expectations This Earnings Season?

Higher alliance revenues from Eliquis, higher sales of Prevnar vaccines and drugs like Vyndaqel/Vyndamax are likely to have contributed to Pfizer's (PFE) sales growth in Q4.

SNY : 48.49 (-0.66%)
PFE : 43.79 (-1.04%)
NVO : 138.09 (+0.40%)
BNTX : 143.66 (+0.79%)
Novavax (NVAX) COVID Jab Aids Growth, Overdependence A Woe

Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.

PFE : 43.79 (-1.04%)
MRNA : 189.35 (-2.01%)
NVAX : 11.29 (+2.82%)
BNTX : 143.66 (+0.79%)
Novavax (NVAX) Gets Nod for COVID-19 Booster Jab in South Korea

Novavax's (NVAX) COVID-19 vaccine gets approval in South Korea as a booster dose in adults 18 years and older.

PFE : 43.79 (-1.04%)
MRNA : 189.35 (-2.01%)
NVAX : 11.29 (+2.82%)
BNTX : 143.66 (+0.79%)
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

Sector ETF report for FBT

FBT : 163.66 (+0.13%)
MRNA : 189.35 (-2.01%)
IBB : 137.23 (+0.05%)
EXAS : 67.48 (+3.75%)
XBI : 89.39 (+0.90%)
BNTX : 143.66 (+0.79%)
Novavax (NVAX) Names John Jacobs as New CEO, Shares Rise

Novavax (NVAX) appoints John C. Jacobs as its new president and chief executive officer, effective Jan 23, 2023.

PFE : 43.79 (-1.04%)
MRNA : 189.35 (-2.01%)
NVAX : 11.29 (+2.82%)
BNTX : 143.66 (+0.79%)
2 Top Biotech Stocks to Buy Right Now

These two pharmaceutical companies pay market-beating dividends to shareholders.

PFE : 43.79 (-1.04%)
BNTX : 143.66 (+0.79%)
NVS : 89.49 (-0.39%)
Novavax (NVAX) Starts A New Study on COVID-Flu Combo Jab

Novavax (NVAX) initiates a mid-stage study evaluating its COVID-19-Influenza combination and standalone influenza vaccines in adults aged 50 through 80 years.

PFE : 43.79 (-1.04%)
MRNA : 189.35 (-2.01%)
NVAX : 11.29 (+2.82%)
BNTX : 143.66 (+0.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BioNTech SE is a biotechnology company. It develops and commercializes immunotherapies for cancer and other diseases. BioNTech SE is based in Mainz, Germany.

See More

Key Turning Points

3rd Resistance Point 147.73
2nd Resistance Point 145.84
1st Resistance Point 144.75
Last Price 143.66
1st Support Level 141.76
2nd Support Level 139.87
3rd Support Level 138.78

See More

52-Week High 189.07
Fibonacci 61.8% 161.57
Fibonacci 50% 153.08
Fibonacci 38.2% 144.58
Last Price 143.66
52-Week Low 117.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar